drugset / Trial / NCT02398747
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to investigate the safety and tolerability of continuous and/or intermittent dosing of AZD2014 when given orally to patients with advanced solid malignancies.
Timeline
- Start
- 2015-03-17
- Primary completion
- 2024-04-12
- Completion
- 2024-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vistusertib | Small molecule | 25 mg | Oral |
| Subject | Vistusertib | Small molecule | 50 mg | Oral |
| Subject | Vistusertib | Small molecule | 125 mg | Oral |
| Background | Paclitaxel | Small molecule | — | — |